《骨質(zhì)疏松癥臨床治療生物制劑循證用藥指南》推薦意見外審:一項(xiàng)橫斷面調(diào)查
中圖分類號(hào)R969.3 文獻(xiàn)標(biāo)志碼A 文章編號(hào) 1001-0408(2025)09-1025-05
DOI 10.6039/j.issn.1001-0408.2025.09.01
ABSTRACT OBJECTIVE To assess the scientific rigor, clarityandfeasibilityoftherecommendationsofthe GuidelinesforEvidence-basedUseofBiological Agentsforthe Clinical TreatmentofOsteoporosis(hereinafterreferredtoas theGuideline)through external review,in order to further revise andimprovetheGuidelinerecommendations. METHODS This study employed a cross-sectional survey research design,a convenience sampling method was adopted
toselectfrontlinemedicalworkersinthefieldfosteoporosis(includingclnicaldoctors,iicalpharmacistsandurses)aswel aspatientsortheirfamilymembers.Externalreviewwasconductedthroughacombinationofclosed-endedandopen-ended electronicquestionnairestogetfeedbackfromthemontheappreciation,clarityandfeasibilityofthe32preliminary recommendationsintheGuideline.RESULTSAtotalof90externalreviewsubjetsfrom15hospitalswerecollected,including45 clinicaldoctors,15clinicalpharmacists,15nursesand15patientsortheirfamilymembers.Theoverallappreciationdegreeof recommendations was 9 9 . 3 8 % ,the overall clarity degree of recommendationswas 9 8 . 9 2 % ,and the overall feasibility degree of recommendations was 9 9 . 6 5 % . At the same time,111 subjective suggestions were collected,which provided an important reference forthefurtherimprovementoftheGuidelinerecommendations.Basedontheabovefedback,theGuidelinesteeringcommiteeand coreexpert grouprevisedthewordingof12draftrecommendationswithout deletion,andfinallydetermined32recommendations. CONCLUSIONSTheexternalreviewprovidesanimportantbasis forthefinalformationof theGuideline,furtherimproves the scientificrigorlarityandfeasibityofthecommendations,ndesuresthestandardization,practicalityandimplementabilityof the Guideline.
KEYWORDSosteoporosis;biological agent;evidence-based medication guideline;external review;recommendations
臨床實(shí)踐指南是醫(yī)學(xué)領(lǐng)域的重要指導(dǎo)性文件,其基于當(dāng)前可獲得的最佳證據(jù),為臨床提供科學(xué)、權(quán)威且規(guī)范的治療建議。(剩余7668字)
- 《骨質(zhì)疏松癥臨床治療生物制劑循...
- 中美日藥品說明書適老化管理的對(duì)...
- 我國(guó)航空醫(yī)療救援藥品使用現(xiàn)狀分...
- 基于定性、定量及化學(xué)模式識(shí)別分...
- 溫脾通絡(luò)開竅方抑制AD小鼠神經(jīng)...
- 鉤苞大丁草的HPLC指紋圖譜建...
- 雙術(shù)湯對(duì)大鼠的安全性及改善消化...
- 指紋圖譜結(jié)合含量測(cè)定分析黃芪悶...
- 不同基原積實(shí)的多組分含量測(cè)定及...
- 匹妥布替尼在大鼠體內(nèi)的代謝產(chǎn)物...
- 檸檬苦素對(duì)妊娠期糖尿病大鼠腎臟...
- 司美格魯肽對(duì)比卡格列凈治療二甲...
- 兒童患者萬古霉素穩(wěn)態(tài)血藥濃度谷...
- 基于病例報(bào)告文獻(xiàn)的妊娠期使用磺...
- 難治性化療所致惡心嘔吐的列線圖...
- 不同劑型短效rhGH治療矮小癥...
- 我國(guó)醫(yī)療機(jī)構(gòu)藥學(xué)監(jiān)護(hù)開展現(xiàn)狀調(diào)...
- 利用ECHO模型評(píng)價(jià)藥學(xué)質(zhì)控對(duì)...
- 家庭醫(yī)生制度下藥師參與腦卒中患...
- 羅特西普治療骨髓增生異常綜合征...
- 替爾泊肽用于2型糖尿病和長(zhǎng)期體...
- 姜黃素抗抑郁作用機(jī)制的研究進(jìn)展...